Hematologic Cancer News and Features

Rituximab vs Splenectomy: Response Similar in Immune Thrombocytopenic Purpura

Rituximab vs Splenectomy: Response Similar in Immune Thrombocytopenic Purpura

Results of a retrospective single-center study showed that response to rituximab vs splenectomy as second-line therapy for steroid-refractory ITP was not significantly different between the 2 treatments.

Combination of Western Care With Chinese Medicine Shows Potential in ITP

Combination of Western Care With Chinese Medicine Shows Potential in ITP

The pathogenesis of idiopathic thrombocytopenic purpura (ITP) may be associated with Th17 helper T cells.

Role of Polymorphisms in Idiopathic Thrombocytopenic Purpura: A Review

Role of Polymorphisms in Idiopathic Thrombocytopenic Purpura: A Review

The main cause of ITP remains unidentified; however, researchers suggest that certain polymorphisms in respective genes are potential factors for ITP.

Value of Type and Crossmatch Prior to Daratumumab Administration

Value of Type and Crossmatch Prior to Daratumumab Administration

If type and crossmatch is obtained before initiating treatment with daratumumab, what good would that do if a transfusion is required a month later?

Induction Regimens for Untreated Multiple Myeloma Compared for ORR, OS, PFS

Induction Regimens for Untreated Multiple Myeloma Compared for ORR, OS, PFS

Comparison study demonstrates early response and survival benefits of VTD, VTDC, and TAD regimens in transplant-eligible patients with newly diagnosed multiple myeloma.

Rare Case of Langerhans Cell Histiocytosis With Prior ITP Highlights Diagnostic Challenge for Clinicians

Rare Case of Langerhans Cell Histiocytosis With Prior ITP Highlights Diagnostic Challenge for Clinicians

A rare case of Langerhans cell histiocytosis (LCH) in a patient with idiopathic thrombocytopenic purpura (ITP) highlights the difficulty in diagnosing LCH.

Current, Emerging Systemic and Targeted Therapies for Pediatric Leukemia: A Review

Current, Emerging Systemic and Targeted Therapies for Pediatric Leukemia: A Review

In this review, investigators discuss current and emerging treatments for acute lymphocytic leukemia and acute myeloid leukemia in pediatric patients.

Long-Term Use of TPO Receptor Agonist Safe in CLL-Associated Immune Thrombocytopenia

Long-Term Use of TPO Receptor Agonist Safe in CLL-Associated Immune Thrombocytopenia

Case study demonstrates the effectiveness of long-term treatment with an oral nonpeptide receptor agonist in a 69-year-old male patient with CLL-associated ITP.

Immune Thrombocytopenia (Fact Sheet)

Immune Thrombocytopenia (Fact Sheet)

This fact sheet examines immune thrombocytopenia (ITP), including patient outlook, treatment, and ITP in pregnancy.

Navigating Patients With Hematologic Cancers

Navigating Patients With Hematologic Cancers

An effective nurse navigator approach involves removing barriers to good care, such as differences in health care delivery systems, poor communication, and financial impediments.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs